Abstracts tagged "lupus nephritis and proteinuria"

Abstract Number: 1558 • 2019 ACR/ARP Annual Meeting
Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?
Whitney Bembry¹, Dasha Lopez ², Christopher Mesa ³, Nirupa Patel ³ and Myriam Guevara ⁴, ¹Tulane University School of Medicine, New Orleans, LA, ²Baton Rouge General Hospital, Baton Rouge, LA, ³Louisiana State University School of Medicine, New Orleans, LA, ⁴Louisiana State University School of Medicine, New Orleans
Background/Purpose: Evidence of podocyte effacement on electron microscopy and significant proteinuria in a systemic lupus erythematosus (SLE) patient with biopsy proven minimal mesangial (MM), mesangial…
Abstract Number: 662 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Non-Albumin Proteinuria for Severity Assessment of Tubulointerstitial Inflammation in Lupus Nephritis
Oh Chan Kwon¹, Seokchan Hong¹, Jung Sun Lee², Byeongzu Ghang¹, Doo-Ho Lim³, Wook Jang Seo⁴, Yong-Gil Kim¹, Chang Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South), ⁴Seoul Veterans Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: Tubulointerstitial inflammation (TI) has been shown to have prognostic significance in renal outcome of lupus nephritis. Considering that the type of protein excreted in…
Abstract Number: 1668 • 2017 ACR/ARHP Annual Meeting
Identification of a Serum Measure of Lupus Nephritis Activity That Detects Molecular Pathways and Mechanisms Implicated in Renal Damage
Mikhail Olferiev¹, Dina Greenman², David Fernandez¹, Kerry Merritt¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Up to 60% of SLE patients develop renal involvement, and renal injury is an important predictor of mortality in patients with SLE. Kidney biopsy…
Abstract Number: 2079 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Renoprotective Approaches in Lupus Nephritis: More Than Just Immunosuppression
Maite Castro¹, Eduardo Ferreira Borba¹, Michelle Lopes¹, Sandra G. Pasoto², Eloisa Bonfá¹ and Luciana Seguro², ¹Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Hypertension and persistent proteinuria are risk factors for renal disease progression and are associated with high salt intake, poor adherence to medication and smoking.…
Abstract Number: 599 • 2013 ACR/ARHP Annual Meeting
Association Between Serum Leptin and Adiponectin Levels With The Severity Of Proteinuria In Lupus Nephritis
Valeria Diaz-Rizo¹, Nicte Selene Fajardo-Robledo², Alan Joel Ruiz-Padilla², Dalia Sanchez-Mosco³, Tania Marlene Rodriguez-Hernandez⁴, Xochitl Trujillo⁵, Miguel Huerta⁵, Monica Vazquez del Mercado⁶, Laura Gonzalez-Lopez⁴ and Jorge Ivan Gamez-Nava⁷, ¹Doctorado en Ciencias Médicas, Centro Universitario de Investigación Biomédica, Universidad de Colima; UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ²Fisiología, Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, ³Centro Universitario de Investigación Biomédica, Universidad de Colima; Hospital General Regional 110 IMSS, Guadalajara, Jalisco, Mexico, ⁴Departamento de Medicina Interna/Rheumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, ⁵Centro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Mexico, ⁶Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁷UMAE, Centro Médico Nacional de Occidente, IMSS; Doctorado en Farmacología, Universidad de Guadalajara, Jalisco, Mexico
Background/Purpose: To identify the association between serum leptin and adiponectin levels and proteinuria secondary to lupus nephritis in women with systemic lupus erythematosus (SLE). Methods:…
Abstract Number: 842 • 2012 ACR/ARHP Annual Meeting
Partial and Complete Recovery From Proteinuria in Lupus Nephritis Patients Receiving Standard of Care Treatment
Zahi Touma¹, D. D. Gladman², Dominique Ibanez³ and Murray B. Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: In the majority of trials on lupus, partial proteinuria recovery (PPR) (≥ 50% decrease in the proteinuria level) is a component of the composite…
Abstract Number: 628 • 2012 ACR/ARHP Annual Meeting
Urinary Heparanase Activity Is Elevated in Patients with Lupus Nephritis and Correlate with Protein Excretion
Ki-Jo Kim¹, In-Woon Baek², Chong-Hyeun Yoon³, Wan-Uk Kim² and Chul-Soo Cho⁴, ¹Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, ²Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁴Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: The heparin sulphate proteoglycans (HSPGs) in the glomerular basement membrane (GBM) play an important role in the charge-selective permeability of the glomerular filter. The…
Abstract Number: 2681 • 2012 ACR/ARHP Annual Meeting
Blocking the Serum Protease Inhibitor Activity of Plasminogen Activator Inhibitor-1 Protects Mice From Development of Glomerulonephritis in a Model of Lupus Nephritis
Brian Naiman¹, Tracy Delaney¹, Lily Cheng², Philip Brohawn², Chris Morehouse², Christopher Groves¹, Isabelle de-Mendez³, Dominic Corkill⁴, Anthony Coyle⁵, Ronald Herbst¹ and Jane Connor¹, ¹Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³Research, MedImmune, LLC, Cambridge, United Kingdom, ⁴Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Cambridge, United Kingdom, ⁵Centers for Therapeutic Innovation, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA
Background/Purpose: Lupus nephritis is an autoimmune disorder which is characterized by extracellular matrix accumulation driven by immune complex deposition and in which thrombosis and sclerosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].